

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to se⦠read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
$2.24
Price+0.90%
$0.02
$123.159m
Small
-
Premium
Premium
-581.3%
EBITDA Margin-622.2%
Net Profit Margin-580.4%
Free Cash Flow Margin-581.3%
EBITDA Margin-622.2%
Net Profit Margin-580.4%
Free Cash Flow Margin$14.680m
-8.9%
1y CAGR-0.5%
3y CAGR+0.5%
5y CAGR-$70.489m
+4.2%
1y CAGR+6.3%
3y CAGR+6.5%
5y CAGR-$1.24
+3.1%
1y CAGR+2.7%
3y CAGR+3.3%
5y CAGR$241.479m
$272.132m
Assets$30.653m
Liabilities$23.028m
Debt8.5%
-0.3x
Debt to EBITDA-$49.879m
-7.9%
1y CAGR+8.1%
3y CAGR+7.7%
5y CAGR